LAVAL, QC—Bausch Health Companies has announced that Dr. Yehia Hashad will join Bausch + Lomb Corp. as executive vice president of research & development (R&D) and chief medical officer (CMO), effective Jan. 31. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11 years he held various roles, including leading Allergan's global clinical development program for its eyecare portfolio. Prior to that, he was with Novartis Pharma AG for five years, where he focused on ophthalmology, and also with T3A Pharma Group for nearly 10 years.

"I am excited that Dr. Hashad will lead the R&D organization and serve as CMO at Bausch + Lomb. He brings more than 25 years of experience working in leading multinational pharmaceutical companies, including expertise in the vision care field, particularly ophthalmic pharmaceuticals," said Joseph C. Papa, chairman and CEO of Bausch Health. "Dr. Hashad will play a critical role in helping to shape the future of R&D at Bausch + Lomb."
Most recently, Dr. Hashad was with Allergan/AbbVie where he served as senior vice president and head of R&D for Allergan Aesthetics from 2020 through August 2021. There, he oversaw the development of more than 40 programs that spanned pharmaceutical products, fillers, reconstructive surgery, devices and consumer skin care. From 2010 until Allergan's acquisition by AbbVie in 2020, Dr. Hashad held a number of executive R&D positions at Allergan, including senior vice president and head of global clinical development; vice president and global head of clinical development, ophthalmology, dermatology and medical aesthetics; and vice president and global head of the ophthalmology and retina therapeutic areas.
Prior to Allergan, Dr. Hashad spent five years with Novartis Pharma AG, where he served as a global medical director for age-related macular degeneration-related treatments Visudyne and Lucentis and as a medical director, ophthalmology, for the European region. From 1996 to 2005, he held positions of increasing responsibility at T3A Pharma Group.
Dr. Hashad obtained his M.S.c. in medical and surgical ophthalmology from Cairo University and a business degree from INSEAD in France. He previously served on the boards of The Glaucoma Research Foundation and the National Alliance of Eye and Vision Research and is currently a board adviser for the University of California Irvine Research Center.